102 results on '"Sieper, Joachim"'
Search Results
2. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
- Author
-
Dougados, Maxime, Wei, James Cheng-Chung, Landewé, Robert, Sieper, Joachim, Baraliakos, Xenofon, Van den Bosch, Filip, Maksymowych, Walter P, Ermann, Joerg, Walsh, Jessica A, Tomita, Tetsuya, Deodhar, Atul, van der Heijde, Désirée, Li, Xiaoqi, Zhao, Fangyi, Bertram, Clinton C, Gallo, Gaia, Carlier, Hilde, and Gensler, Lianne S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adalimumab ,Antibodies ,Monoclonal ,Humanized ,Antirheumatic Agents ,Double-Blind Method ,Drug Substitution ,Female ,Humans ,Male ,Radiography ,Severity of Illness Index ,Spondylarthritis ,Time Factors ,Treatment Outcome ,Tumor Necrosis Factor Inhibitors ,COAST-V and COAST-W Study Groups ,DMARDs ,ankylosing spondylitis ,spondyloarthritis ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
OBJECTIVES:To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W). METHODS:Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W. At week 16, patients receiving ixekizumab continued their assigned treatment; patients receiving PBO or ADA were rerandomised 1:1 to IXE Q2W or IXE Q4W (PBO/IXE, ADA/IXE) through week 52. RESULTS:In COAST-V, Assessment of SpondyloArthritis international Society 40 (ASAS40) responses rates (intent-to-treat population, non-responder imputation) at weeks 16 and 52 were 48% and 53% (IXE Q4W); 52% and 51% (IXE Q2W); 36% and 51% (ADA/IXE); 19% and 47% (PBO/IXE). Corresponding ASAS40 response rates in COAST-W were 25% and 34% (IXE Q4W); 31% and 31% (IXE Q2W); 14% and 39% (PBO/IXE). Both ixekizumab regimens sustained improvements in disease activity, physical function, objective markers of inflammation, QoL, health status and overall function up to 52 weeks. Safety through 52 weeks of ixekizumab was consistent with safety through 16 weeks. CONCLUSION:The significant efficacy demonstrated with ixekizumab at week 16 was sustained for up to 52 weeks in bDMARD-naive and TNFi-experienced patients. bDMARD-naive patients initially treated with ADA demonstrated further numerical improvements after switching to ixekizumab. Safety findings were consistent with the known safety profile of ixekizumab. TRIAL REGISTRATION NUMBER:NCT02696785/NCT02696798.
- Published
- 2020
3. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
- Author
-
Smolen, Josef S, Schöls, Monika, Braun, Jürgen, Dougados, Maxime, FitzGerald, Oliver, Gladman, Dafna D, Kavanaugh, Arthur, Landewé, Robert, Mease, Philip, Sieper, Joachim, Stamm, Tanja, Wit, Maarten de, Aletaha, Daniel, Baraliakos, Xenofon, Betteridge, Neil, Bosch, Filip van den, Coates, Laura C, Emery, Paul, Gensler, Lianne S, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kvien, Tore K, Inman, Robert D, McInnes, Iain B, Maccarone, Mara, Machado, Pedro M, Molto, Anna, Ogdie, Alexis, Poddubnyy, Denis, Ritchlin, Christopher, Rudwaleit, Martin, Tanew, Adrian, Thio, Bing, Veale, Douglas, Vlam, Kurt de, and van der Heijde, Désirée
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Arthritis ,Autoimmune Disease ,Clinical Research ,Rare Diseases ,Inflammatory and immune system ,Advisory Committees ,Arthritis ,Psoriatic ,Axis ,Cervical Vertebra ,Consensus ,Decision Making ,Humans ,Severity of Illness Index ,Spondylitis ,Ankylosing ,Ankylosing Spondylitis ,Outcomes Research ,Psoriatic Arthritis ,Spondyloarthritis ,Treatment ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.
- Published
- 2018
4. Treatment of Axial Spondyloarthritis: What Does the Future Hold?
- Author
-
Poddubnyy, Denis and Sieper, Joachim
- Published
- 2020
- Full Text
- View/download PDF
5. Mechanism of New Bone Formation in Axial Spondyloarthritis
- Author
-
Poddubnyy, Denis and Sieper, Joachim
- Published
- 2017
- Full Text
- View/download PDF
6. An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus
- Author
-
Schulte-Wrede, Ursula, Sörensen, Till, Grün, Joachim R., Häupl, Thomas, Hirseland, Heike, Steinbrich-Zöllner, Marta, Wu, Peihua, Radbruch, Andreas, Poddubnyy, Denis, Sieper, Joachim, Syrbe, Uta, and Grützkau, Andreas
- Published
- 2018
- Full Text
- View/download PDF
7. Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study
- Author
-
Grazio, Simeon, Kusić, Zvonko, Cvijetić, Selma, Grubišić, Frane, Balenović, Antonija, Nemčić, Tomislav, Matijević-Mikelić, Valentina, Punda, Marija, and Sieper, Joachim
- Published
- 2012
- Full Text
- View/download PDF
8. Chronischer Rückenschmerz — wann an entzündlich-rheumatische Ursachen denken?
- Author
-
Poddubnyy, Denis, Rudwaleit, Martin, and Sieper, Joachim
- Published
- 2011
- Full Text
- View/download PDF
9. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
- Author
-
Deodhar, Atul, van der Heijde, Désirée, Sieper, Joachim, Van den Bosch, Filip, Maksymowych, Walter P., Kim, Tae‐Hwan, Kishimoto, Mitsumasa, Ostor, Andrew, Combe, Bernard, Sui, Yunxia, Chu, Alvina D., and Song, In‐Ho
- Subjects
ANKYLOSING spondylitis ,NONSTEROIDAL anti-inflammatory agents ,JANUS kinases ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,BLIND experiment ,DESCRIPTIVE statistics ,NEUROTRANSMITTER uptake inhibitors ,STATISTICAL sampling ,ADVERSE health care events ,PHARMACODYNAMICS - Abstract
Objective: To report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS). Methods: In the SELECT‐AXIS 1 study, adults with active AS and an inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive upadacitinib 15 mg once daily or placebo. At week 14, patients who had been randomized to receive placebo were switched to upadacitinib, and all patients continued in the open‐label extension and received upadacitinib up to week 104; interim data up to week 64 are reported herein. Results: Of 187 patients, 178 completed week 14 on study drug and entered the open‐label extension. Similar proportions of patients in either group (continuous upadacitinib or placebo‐to‐upadacitinib) achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40) or Ankylosing Spondylitis Disease Activity Score (ASDAS) showing low disease activity at week 64: ≥70% of patients achieved these end points based on nonresponder imputation (NRI) and ≥81% based on as‐observed analyses. Furthermore, ≥34% (NRI) and ≥39% (as‐observed analysis) achieved ASDAS showing inactive disease or ASAS showing partial remission at week 64. Mean changes from baseline (week 0) to week 64 in pain, function, and inflammation showed consistent improvement or sustained maintenance through the study. Among 182 patients receiving upadacitinib (237.6 patient‐years), 618 adverse events (260.1 per 100 patient‐years) were reported. No serious infections, major adverse cardiovascular events, venous thromboembolic events, gastrointestinal perforation, or deaths were reported. Conclusion: Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 1 year. Patients who switched from placebo to upadacitinib at week 14 showed similar efficacy versus those who received continuous upadacitinib. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis.
- Author
-
Poddubnyy, Denis, Proft, Fabian, Spiller, Laura, Protopopov, Mikhail, Rodriguez, Valeria Rios, Muche, Burkhard, Rademacher, Judith, Torgutalp, Murat, Vahldiek, Janis Lucas, Sieper, Joachim, and Redeker, Imke
- Subjects
INTERNET ,ANKYLOSING spondylitis ,MEDICAL screening ,PRE-tests & post-tests ,DESCRIPTIVE statistics - Abstract
Objective To evaluate the diagnostic value of SpA parameters and their combination for the diagnosis of axial SpA in patients with an a priori different probability of the diagnosis. Methods A total of 361 patients with chronic back pain and suspicion of axial SpA (181 referred by primary care physicians or orthopaedists, 180 recruited via an online screening tool) received a structured rheumatologic examination, which resulted into a diagnosis or exclusion of axial SpA. The prevalence of axial SpA indicating the pre-test probability was 40% in the physician-referred subgroup and 20% in the online screening subgroup. Sensitivities, specificities and likelihood ratios for SpA features were determined in both subgroups and the respective post-test probabilities of axial SpA were calculated. Results The relative diagnostic value of single SpA features varied substantially between the groups with different referral pathways. For instance, HLA-B27 positivity increased the probability of the presence of axial SpA by 35% to 55% in online-screened patients and by 22% to 62% in physician-referred patients. The absence of HLA-B27 resulted in a sharp decrease in the probability of the presence of axial SpA in physician-referred patients (from 40% to 6%). This decrease was less sharp in the online screening group (from 20% to 10%). These differences were especially relevant in patients with a small number (one to two) of positive SpA features. Conclusion The diagnostic value of SpA features varies in different patient populations, which should be considered in the diagnostic approach. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care
- Author
-
Poddubnyy, Denis, Callhoff, Johanna, Spiller, Inge, Listing, Joachim, Braun, Juergen, Sieper, Joachim, and Rudwaleit, Martin
- Subjects
REFERRAL ,STRATEGIES ,ANKYLOSING-SPONDYLITIS ,PERFORMANCE ,spondyloarthritis ,RECOMMENDATIONS ,PREVALENCE ,ankylosing spondylitis ,Medicine and Health Sciences ,SOCIETY CLASSIFICATION CRITERIA ,epidemiology ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,low back pain - Abstract
Objective : Inflammatory back pain (IBP), the key symptom of axial spondyloarthritis (axSpA), including ankylosing spondylitis, has been proposed as a screening test for patients presenting with chronic back pain in primary care. The diagnostic accuracy of IBP in the rheumatology setting is unknown. Methods: Six rheumatology centres, representing secondary and tertiary rheumatology care, included routinely referred patients with consecutive chronic back pain with suspicion of axSpA. IBP (diagnostic test) was assessed in each centre by an independent (blinded) rheumatologist; a second (unblinded) rheumatologist made the diagnosis (axSpA or no-axSpA), which served as reference standard. Results: Of 461 routinely referred patients, 403 received a final diagnosis. IBP was present in 67.3%, and 44.6% (180/403) were diagnosed as axSpA. The sensitivity of IBP according to various definitions (global judgement, Calin, Berlin, Assessment of SpondyloArthritis international Society criteria for IBP) was 74.4%-81.1 % and comparable to published figures, whereas the specificity was unexpectedly low (25.1%-43.9%). The resulting positive likelihood ratios (LR+) were 1.1-1.4 and without major differences between sets of IBP criteria. The presence of IBP according to various definitions increased the probability of axSpA by 2.5%-8.4% only (from 44.6% to 47.1%-53.0%). Conclusions: The diagnostic utility of IBP in the rheumatology setting was smaller than expected. However, this was counterbalanced by a high prevalence of IBP among referred patients, demonstrating the effective usage of IBP in primary care as selection parameter for referral to rheumatology. Notably, this study illustrates potential shifts in specificity and LR+ of diagnostic tests if these tests are used to select patients for referral.
- Published
- 2018
12. Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial.
- Author
-
Proft, Fabian, Weiß, Anja, Torgutalp, Murat, Protopopov, Mikhail, Rodriguez, Valeria Rios, Haibel, Hildrun, Behmer, Olaf, Sieper, Joachim, and Poddubnyy, Denis
- Abstract
Aims: Long-term data on TNFi treatment in patients with axSpA is scarce. The objective of this analysis was to assess long-term clinical efficacy of etanercept in early axSpA [including both non-radiographic and radiographic axSpA forms], who participated in the long-term (until year 10) extension of the ESTHER-trial. Methods: In the previously reported ESTHER-trial, patients with early active axSpA were randomized to treatment with etanercept (n = 40) or sulfasalazine (n = 36) during the first year. Patients in remission discontinued their therapy and were followed up until the end of year 2; in case of remission-loss, etanercept was (re)-introduced and continued until the end of year 10. If remission was not achieved at year 1, patients continued receiving (or were switched to) etanercept for up to 10 years. Results: A total of 19 patients (12 with r-axSpA and 7 with nr-axSpA at baseline) out of the initial 76 patients (= 25%) completed year 10 of the study. In the entire group, a sustained clinical response was seen over 10 years of follow up in the as-observed analysis. Completers were significantly more often male and showed lower values of patient and physician global assessments of disease activity, Ankylosing Spondylitis Disease Activity Score (ASDAS), and Ankylosing Spondylitis Quality of Life questionnaire (ASQoL) scores at baseline as compared with non-completers. When analyzing clinical data of the completers, mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) values were constantly below 2 and mean ASDAS below 2.1 during follow up with no statistically significant differences between the r-axSpA and nr-axSpA subgroups. A total of 39 serious adverse events were documented over the 10 years, while six of them were seen as possibly associated with the etanercept treatment, which led in five patients to treatment discontinuation. Conclusion: A sustained clinical response was observed over the 10 years of the study with comparable response and drop-out rates between r-axSpA and nr-axSpA. Etanercept was well tolerated across the entire treatment period and showed a good safety profile with no new safety signals. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis.
- Author
-
Rodriguez, Valeria Rios, Llop, Maria, Protopopov, Mikhail, Sieper, Joachim, Haibel, Hildren, Proft, Fabian, Rudwaleit, Martin, and Poddubnyy, Denis
- Subjects
RELIABILITY (Personality trait) ,RESEARCH evaluation ,ANKYLOSIS ,RADIOGRAPHY ,SPONDYLOARTHROPATHIES ,DESCRIPTIVE statistics ,STATISTICAL correlation ,LUMBAR vertebrae ,LONGITUDINAL method - Abstract
Objective The aim was to investigate the reliability and validity of radiographic sacroiliitis assessment in anteroposterior (AP) lumbar radiographs compared with conventional pelvic radiographs in patients with axial spondyloarthritis (axSpA). Methods Patients from the German Spondyloarthritis Inception Cohort were selected based on the availability of pelvic and AP lumbar radiographs with visible SI joints at baseline and year 2. Two readers scored the images independently in a random order according to the modified New York criteria. The sacroiliitis sum score was calculated as the mean of both readers. Patients were classified as radiographic (r-)axSpA if radiographic sacroiliitis of grade ≥2 bilaterally or grade ≥3 unilaterally was present in the opinion of both readers and as non-radiographic (nr-)axSpA otherwise. The reliability and validity of sacroiliitis assessment in AP lumbar radiographs was assessed using intraclass correlation coefficients (ICCs), absolute agreement and κ statistics. Results A total of 226 sets of radiographs were scored from 113 patients included in the study. The ICC for the sacroiliitis sum score was 0.91 at both baseline and year 2. A total of 62 (54.9%) and 55 (48.7%) patients were classified as r-axSpA at baseline and 65 (57.5%) and 60 (53.1%) patients at year 2 based on evaluation of pelvic and AP lumbar radiographs, respectively. The absolute agreement between the methods on the classification was 84.9 and 85.0% at baseline and year 2, respectively, with the κ of 0.70 at both time points. Conclusion Radiographic sacroiliitis can be assessed in AP lumbar radiographs with a similar reliability to conventional pelvic radiographs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa.
- Author
-
Proft, Fabian, Spiller, Laura, Redeker, Imke, Protopopov, Mikhail, Rodriguez, Valeria Rios, Muche, Burkhard, Rademacher, Judith, Weber, Anne-Katrin, Lüders, Susanne, Torgutalp, Murat, Sieper, Joachim, and Poddubnyy, Denis
- Abstract
• Long diagnostic delay in axial SpA is often related to a late referral to rheumatologist. • The proportion of axial SpA among self-referred patients (19.4%) was clearly higher than the assumed 5% prevalence of axial SpA in patients with chronic back pain. • Online self-referral tool might be considered as an early recognition instrument for specialized rheumatology centers in addition to physician based-referrals and as a medium for raising awareness of axial SpA in general. The diagnostic delay in axial spondyloarthritis (axial SpA) remains unacceptably high, with one of the reasons being a late referral. Structured physician-based referral programs are able to improve early diagnosis, but lack of implementation is still an issue. The objective of this study was to evaluate an online self-referral (OSR) tool for patients with back pain and to compare it to an established physician-based referral tool. Patients with back pain were included if they either fulfilled the requirements of the OSR tool or were referred by a physician using the Berlin referral tool. Rheumatologists in the specialized center performed a structured assessment in all patients that resulted in the final diagnosis of axial SpA / no axial SpA. Furthermore, we attempted to optimize the OSR tool in terms of maximizing the specificity constrained by a sensitivity of at least 90% of the original strategy. 361 consecutive patients (180 via the OSR and 181 via the Berlin referral tool) were included in the study. A total of 35 patients (19.4%) in the self-referral group and 71 patients (39.2%) in the physician-referral group were finally diagnosed with axial SpA. Axial SpA patients from the OSR group were more often HLA-B27 negative, females, and were more frequently at a non-radiographic stage as compared to axial SpA patients who came via the physician-based tool. Both groups had, however, a similar disease burden. According to the pre-defined selection criterion we identified an optimized combination of ≥2 IBP parameters and ≥1 other SpA parameters (in addition to both stem parameters). Despite the better performance of the physician-based referral strategy, the proportion of axial SpA among self-referred patients (19.4%) was clearly higher than the assumed 5% prevalence of axial SpA in patients with chronic back pain. Based on our data driven approach the performance of the OSR strategy could be further improved if at least two IBP parameters plus one additional SpA parameter had to be present in addition to the stem parameters. The OSR tool can be used in specialized centers in addition to a physician-based referral strategy to improve early diagnosis and to increase awareness of axial SpA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.
- Author
-
Winthrop, Kevin L., Weinblatt, Michael E., Bathon, Joan, Burmester, Gerd R., Mease, Philip J., Crofford, Leslie, Bykerk, Vivian, Dougados, Maxime, Rosenbaum, James Todd, Mariette, Xavier, Sieper, Joachim, Melchers, Fritz, Cronstein, Bruce N., Breedveld, Ferry C., Kalden, Joachim, Smolen, Josef S., and Furst, Daniel
- Subjects
DRUG therapy for rheumatism ,EXPERIMENTAL design ,PSORIATIC arthritis ,RESEARCH ,CLINICAL trials ,NEUROPHYSIOLOGY ,ANKYLOSING spondylitis ,RHEUMATOLOGY ,CONFERENCES & conventions ,DRUG therapy ,RHEUMATOID arthritis ,SYSTEMIC lupus erythematosus ,NEEDS assessment ,RHEUMATISM ,MEDICAL research - Abstract
Objectives: To detail the greatest areas of unmet scientific and clinical needs in rheumatology.Methods: The 21st annual international Advances in Targeted Therapies meeting brought together more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. During the meeting, breakout sessions were convened, consisting of 5 disease-specific groups with 20-30 experts assigned to each group based on expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus and other systemic autoimmune rheumatic diseases. In each group, experts were asked to identify unmet clinical and translational research needs in general and then to prioritise and detail the most important specific needs within each disease area.Results: Overarching themes across all disease states included the need to innovate clinical trial design with emphasis on studying patients with refractory disease, the development of trials that take into account disease endotypes and patients with overlapping inflammatory diseases, the need to better understand the prevalence and incidence of inflammatory diseases in developing regions of the world and ultimately to develop therapies that can cure inflammatory autoimmune diseases.Conclusions: Unmet needs for new therapies and trial designs, particularly for those with treatment refractory disease, remain a top priority in rheumatology. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.
- Author
-
Sieper, Joachim, Poddubnyy, Denis, and Miossec, Pierre
- Subjects
- *
PSORIATIC arthritis , *ANIMAL models of inflammation , *PATHOLOGY , *ANKYLOSING spondylitis , *MONOCLONAL antibodies , *BONE marrow - Abstract
The cytokines IL-23 and IL-17 have an important role in the pathogenesis of, and as a therapeutic target in, both animal models of chronic inflammation and some human chronic inflammatory diseases. The traditional view is that a main source of IL-17 is T cells and that IL-17 production is under the control of IL-23. IL-17 inhibition has shown good efficacy in clinical trials for ankylosing spondylitis (AS), a subtype of axial spondyloarthritis (axSpA) characterized by radiographic evidence of sacroiliitis. On the basis of data from animal models, genetic studies and the investigation of tissue and blood samples from patients with AS, IL-23 had also been predicted to be important in the pathogenesis of this disease and was therefore considered a potential therapeutic target for axSpA. However, two placebo-controlled, double-blind clinical trials in axSpA of monoclonal antibodies directed against either the p40 protein or the p19 protein of the IL-23 molecule had clear negative results. These findings indicate that IL-23 and IL-17 are at least partly uncoupled in axSpA. Reasons as to why, when and how such an uncoupling might occur are discussed in this Review, with special reference to the unique microenvironment of the subchondral bone marrow in axSpA. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2-year results from a phase 3 trial with subcutaneous loading and maintenance dosing (MEASURE 2)
- Author
-
Sieper, Joachim, Marzo-Ortega, Helena, Zuazo, James, Readie, Aimee, Porter, Brian, and Richards, Hanno B.
- Subjects
ddc: 610 ,secukinumab ,ankylosing spondylitis ,610 Medical sciences ,Medicine - Abstract
Background: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks (wks) in the randomised, double-blind, placebo (PBO)-controlled, Phase 3 MEASURE 2 study (NCT01649375) [ref:1]. Objectives: To evaluate[for full text, please go to the a.m. URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)
- Published
- 2016
- Full Text
- View/download PDF
18. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis.
- Author
-
Rademacher, Judith, Tietz, Lorraine Madeline, Le, Lien, Hartl, Agnes, Hermann, Kay-Geert A., Sieper, Joachim, Mansmann, Ulrich, Rudwaleit, Martin, and Poddubnyy, Denis
- Subjects
NONSTEROIDAL anti-inflammatory agents ,SPINE radiography ,ANKYLOSING spondylitis ,BIOMARKERS ,C-reactive protein ,CALCIUM-binding proteins ,CELL receptors ,COLLAGEN ,CONFIDENCE intervals ,ENZYME-linked immunosorbent assay ,PROTEOLYTIC enzymes ,SEX distribution ,SMOKING ,SPINAL cord diseases ,LEPTIN ,VASCULAR endothelial growth factors ,PREDICTIVE tests ,RECEIVER operating characteristic curves ,ADIPONECTIN ,ROUTINE diagnostic tests ,BLOOD ,DISEASE complications ,DISEASE risk factors - Abstract
Objectives The objective of this study was to examine whether adding biomarkers to routine clinical parameters improves prediction of radiographic spinal progression in axial spondyloarthritis. Methods One hundred and seventeen patients with ankylosing spondylitis who completed the Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) trial were included. Radiographic spinal progression was defined as worsening of the modified Stoke Ankylosing Spondylitis Spine Score by ⩾2 points after 2 years. A clinical prediction model was constructed out of baseline syndesmophytes, elevated CRP, cigarette smoking and male sex. The following serum biomarkers were measured at baseline by ELISA: MMP3, VEGF, calprotectin, leptin, high molecular weight adiponectin, osteoprotegerin, sclerostin, N-terminal telopeptide, procollagen type II N-terminal propeptide and serum amyloid A. Results Repeated cross-validation analyses revealed one biomarker combination with potential added predictive value in addition to the clinical model: leptin + high molecular weight adiponectin + VEGF. This biomarker combination showed an area under the curve (AUC)
Biomarkers = 0.731 (95% CI: 0.614, 0.848), which was numerically superior to the clinical model [AUCClinical = 0.665 (95% CI: 0.553, 0.776)]. A combination of clinical parameters + biomarkers showed an improved predictive value compared with the clinical model reflected by AUCClinical+Biomarkers = 0.768 (95% CI: 0.666, 0.871), though not statistically significant (P = 0.051). However, by considering the part of the receiver operating characteristic curve with a specificity ⩾75% resulting in partial AUC (pAUC), the improvement becomes significant (pAUCClinical+Biomarkers = 0.119; pAUCClinical = 0.053; P = 0.01). Conclusion Biomarkers show potential to improve the prediction of radiographic spinal progression in axial spondyloarthritis when used in addition to the clinical parameters, though the added value seems to be rather small. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
19. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.
- Author
-
Winthrop, Kevin L., Weinblatt, Michael E., Crow, Mary K., Burmester, Gerd R., Mease, Philip J., So, Alexander K., Bykerk, Vivian, Van Vollenhoven, Ronald F., Dougados, Maxime, Kay, Jonathan, Mariette, Xavier, Sieper, Joachim, Melchers, Fritz, Cronstein, Bruce N., Shevach, Ethan, Breedfeld, Ferdinand C., Kalden, Joachim, Smolen, Josef S., and Furst, Daniel E.
- Abstract
To develop a comprehensive listing of the greatest unmet scientific and clinical needs in rheumatology. The 20th annual international Targeted Therapies meeting brought more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. During the meeting, breakout sessions were convened, consisting of five disease-specific groups with 20-30 experts assigned to each group based on expertise. Specific groups included rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, connective tissue diseases and a basic science immunology group spanning all of these clinical domains. In each group, experts were asked to consider recent accomplishments within their clinical domain in the last year and update the unmet needs in three categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. While progress was noted among some of previously identified needs, both new needs were identified and themes from prior meetings were re-iterated: the need for better understanding the heterogeneity within each disease, and for identifying preclinical states of disease allowing treatment and prevention of disease in those at risk, and the elusive ability to cure disease. Within the clinical care realm, improved comorbidity management and patient-centred care continue to be unmet needs, and the need for new and affordable therapeutics was highlighted. Unmet needs for new and accessible targeted therapies, disease prevention and ultimately cure remain a priority in rheumatology. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Spondyloarthritis
- Author
-
Sieper, Joachim, Braun, Jürgen, Sieper, Joachim, and Braun, Jürgen
- Subjects
- Ankylosing spondylitis, Spondyloarthropathies
- Abstract
Edited by Drs. Juergen Braun and Joachim Sieper, this issue of Rheumatic Disease Clinics comprehensively reviews the state of the art of spondyloarthritis (SpA) diagnosis, prognosis, pathogenesis and genetic insights, and treatment. The worldwide burden of SpA now exceeds that of rheumatoid arthritis. General topics covered include inflammatory back pain, pathophysiology, imaging techniques, and therapeutic strategies.
- Published
- 2012
21. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.
- Author
-
Landewé, Robert, Sieper, Joachim, Mease, Philip, Inman, Robert D., Lambert, Robert G., Deodhar, Atul, Marzo-Ortega, Helena, Magrey, Marina, Kiltz, Uta, Xin Wang, Mei Li, Sheng Zhong, Mostafa, Nael M., Apinya Lertratanakul, Pangan, Aileen L., Anderson, Jaclyn K., Wang, Xin, Li, Mei, Zhong, Sheng, and Lertratanakul, Apinya
- Subjects
- *
ADALIMUMAB , *ANKYLOSING spondylitis , *DISEASE remission , *RANDOMIZED controlled trials , *NONSTEROIDAL anti-inflammatory agents , *THERAPEUTICS , *RESEARCH , *RESEARCH methodology , *DRUG withdrawal symptoms , *EVALUATION research , *MEDICAL cooperation , *DISEASE relapse , *COMPARATIVE studies , *BLIND experiment , *STATISTICAL sampling , *SUBCUTANEOUS injections - Abstract
Background: Success of treatment withdrawal in patients with non-radiographic axial spondyloarthritis who are in remission remains unknown. The ABILITY-3 study explored the ability to withdraw adalimumab treatment in patients with non-radiographic axial spondyloarthritis who achieved sustained clinical remission after open-label treatment with adalimumab.Methods: ABILITY-3 was a multicentre, two-period study done in 107 sites in 20 countries. We enrolled adult patients (≥18 years) diagnosed with non-radiographic axial spondyloarthritis, fulfilling Assessment of SpondyloArthritis international Society classification criteria but not the modified New York radiologic criterion, who had objective evidence of active inflammation, active disease, and inadequate response to at least two non-steroidal anti-inflammatory drugs. Patients who achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (<1·3) with open-label adalimumab (40 mg subcutaneously every other week for 28 weeks) at weeks 16, 20, 24, and 28 were randomly assigned (1:1) using an interactive voice or web response system to 40-week, double-blind treatment with adalimumab (continuation) or placebo (withdrawal). The primary efficacy endpoint was the proportion of patients who did not experience a flare (defined as ASDAS ≥2·1 at two consecutive visits) during the double-blind period. Patients who flared were rescued with open-label adalimumab. This study is registered with ClinicalTrials.gov, number NCT01808118.Findings: Between June 27, 2013, and October 22, 2015, 673 patients were enrolled to the study. The trial completed on April 14, 2017. Of 673 enrolled patients, 305 (45%) achieved sustained remission and were randomly assigned to double-blind treatment (152 patients to adalimumab and 153 to placebo). A greater proportion of patients continuing adalimumab than those receiving placebo did not experience a flare (107 [70%] of 152 patients vs 72 [47%] of 153 patients; p<0·0001) up to and including week 68. Among 673 patients receiving adalimumab at any time, 516 (77%) patients reported an adverse event and 28 (4%) experienced a serious adverse event. The most common adverse events in both the adalimumab and placebo groups were nasopharyngitis (25 [16%] vs 20 [13%]), upper respiratory tract infection (20 [13%] vs 12 [8%]), and worsening of axial spondyloarthritis (ten [7%] vs 21 [14%]).Interpretation: In patients with active non-radiographic axial spondyloarthritis who achieved sustained remission with adalimumab, continued therapy was associated with significantly fewer patients flaring than was treatment withdrawal.Funding: AbbVie. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
22. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?
- Author
-
Poddubnyy, Denis and Sieper, Joachim
- Subjects
- *
INTERLEUKINS , *SPONDYLOARTHROPATHIES , *TREATMENT effectiveness , *TUMOR necrosis factors , *CHEMICAL inhibitors , *THERAPEUTICS - Abstract
After about 15 years of experience with the TNF blockers as the only effective drugs in axial spondylarthritis patients who fail conventional treatment, for the first time we see now that another targeted therapy, the inhibition of IL-17, is also effective. By indirect comparison of the treatment effect between the two types of drugs, efficacy seems to be on a similar level. This raises quite a few important questions that are related to both pathogenesis and treatment strategies for which the answers are currently largely unknown, but would be of great relevance for optimizing therapies. In this article, we discuss these questions and ways in which such questions could be answered. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.
- Author
-
Redeker, Imke, Hoffmann, Falk, Callhoff, Johanna, Haibel, Hildrun, Sieper, Joachim, Zink, Angela, and Poddubnyy, Denis
- Subjects
AGE distribution ,ANKYLOSING spondylitis ,COMPARATIVE studies ,MENTAL depression ,DISABILITY evaluation ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,MULTIVARIATE analysis ,PROGNOSIS ,QUALITY of life ,RESEARCH ,RISK assessment ,SACROILIAC joint ,SEX distribution ,SICKNESS Impact Profile ,SPONDYLOARTHROPATHIES ,LOGISTIC regression analysis ,EVALUATION research ,SEVERITY of illness index - Abstract
Objectives: The aim of this study was to assess the psychological well-being and to analyse factors associated with depressive symptoms in axial spondyloarthritis (axSpA).Methods: A stratified random sample of subjects with a diagnosis of axSpA (International Classification of Diseases, Tenth Revision, German Modification M45) was drawn from health insurance data in Germany. These persons received a postal questionnaire on disease-related, psychological and lifestyle factors as well as socioeconomic status. Additional information to verify the axSpA diagnosis was also collected. The psychological well-being was assessed by means of the 5-item WHO Well-Being Index (WHO-5), which is considered a screening tool for depression. The following established cut-offs on the WHO-5 were applied: >50: good well-being, no depressive symptoms; 29-50: mild depressive symptoms; ≤28: moderate-to-severe depressive symptoms. Information on comorbidities, drug prescriptions and non-pharmacological treatment was retrieved from claims data and linked to the questionnaire data.Results: A total of 1736 persons with a confirmed axSpA diagnosis were included. Using the cut-offs on the WHO-5, 533 persons (31%) were found to have moderate-to-severe depressive symptoms, 479 (28%) had mild depressive symptoms and 724 (42%) had a good well-being. Multivariable logistic regression revealed that higher disease activity, higher level of functional impairment, lower income, self-reported stress and lack of exercise, and younger age represent factors associated with moderate-to-severe depressive symptoms.Conclusions: The prevalence of depressive symptoms in axSpA subjects is high and associated with disease-related parameters, socioeconomic status and lifestyle factors. These findings highlight the need for the careful evaluation of depressive symptoms as a part of the management strategy for axSpA. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
24. Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort.
- Author
-
Poddubnyy, Denis, Listing, Joachim, Haibel, Hildrun, Knüppel, Sven, Rudwaleit, Martin, and Sieper, Joachim
- Subjects
ANKYLOSING spondylitis ,CONFIDENCE intervals ,LIFE skills ,LONGITUDINAL method ,REGRESSION analysis ,SPINE - Abstract
Objectives. The aim of the study was to investigate the functional relevance of the development of structural damage in the spine in patients with early axial spondyloarthritis (axSpA). Methods. Altogether, 210 patients with early axSpA (symptom duration ≤10 years) who completed a 2-year clinical and radiographic follow-up in the GErman SPondyloarthritis Inception Cohort were included. An association between structural damage in the spine [modified Stoke AS Spine Score (mSASSS)] and functional status (the BASFI) or spinal mobility (the BASMI) was assessed in a longitudinal linear mixed model analysis; both unstandardized (β) and standardized (βstand) regression coefficients were calculated. Results. There was an association between mSASSS and BASFI: β = 0.05 (95% CI: 0.03, 0.08) and βstand = 0.20 (95% CI: 0.11, 0.59) adjusted for disease activity parameters (the BASDAI and CRP), the presence of definite radiographic sacroiliitis and sex. An association between mSASSS and BASMI was stronger: β = 0.08 (95% CI: 0.05, 0.11) and βstand = 0.41 (95% CI: 0.25, 0.57) adjusted for the same parameters. These data indicate that, over time, an increase of 20 or 12 mSASSS points would be responsible for an increase of one BASFI or one BASMI point, respectively. Disease activity (BASDAI) also showed a significant association with BASFI [β = 0.79 (95% CI: 0.71, 0.86) and βstand = 0.71 (95% CI: 0.63, 0.77)] and BASMI [β = 0.22 (95% CI: 0.15, 0.30) and βstand = 0.28 (95% CI: 0.18, 0.37)]. Conclusion. Structural damage in the spine and disease activity are both determinants of the functional status and spinal mobility in early axSpA. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
- Author
-
van der Heijde, Désirée, Dougados, Maxime, Landewé, Robert, Sieper, Joachim, Maksymowych, Walter P., Rudwaleit, Martin, den Bosch, Filip Van, Braun, Jürgen, Mease, Philip J., Kivitz, Alan J., Walsh, Jessica, Davies, Owen, Bauer, Lars, Hoepken, Bengt, Peterson, Luke, and Deodhar, Atul
- Subjects
ANKYLOSING spondylitis ,CLINICAL medicine ,EVALUATION of medical care ,PATIENT safety ,RESEARCH funding ,SELF-evaluation ,TREATMENT effectiveness ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Objective. The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. Methods. RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease. The assessed outcomes included ASAS20, ASAS40, AS DAS (ASDAS), BASDAI, BASFI and BASMI scores, along with selected measures of remission. Further patient-reported outcomes, peripheral arthritis, enthesitis, uveitis and quality-of-life measures are also reported. Results. Two hundred and eighteen of 325 patients randomized (AS: 121; nr-axSpA: 97) received certolizumab pegol from week 0. Of these, 65% remained in the study at week 204 (AS: 67%; nr-axSpA: 63%). Across all outcomes, for AS and nr-axSpA, sustained improvements were observed to week 204 [week 204 overall axSpA: ASAS20: 54.1% (non-responder imputation); 83.7% (observed case, OC); ASAS40: 44.0% (non-responder imputation); 68.1% (OC); ASDAS inactive disease: 32.1% (last observation carried forward); 31.4% (OC)]. In the safety set (n = 315), there were 292.8 adverse events and 10.4 serious adverse events per 100 patient-years. No deaths were reported. Conclusion. In the first study to evaluate the efficacy of an anti-TNF across both axSpA subpopulations, improvements in clinical and patient-reported outcomes at 24 and 96weeks were sustained through 4 years of treatment, with no new safety signals. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Axial spondyloarthritis.
- Author
-
Sieper, Joachim and Poddubnyy, Denis
- Subjects
- *
ANKYLOSING spondylitis , *ARTHRITIS , *TUMOR necrosis factors , *INTERLEUKIN-17 , *NONSTEROIDAL anti-inflammatory agents - Abstract
The term axial spondyloarthritis covers both patients with non-radiographic and radiographic axial spondyloarthritis, which is also termed ankylosing spondylitis. The disease usually starts in the third decade of life with a male to female ratio of two to one for radiographic axial spondyloarthritis and of one to one for non-radiographic axial spondyloarthritis. More than 90% heritabilty has been estimated, the highest genetic association being with HLA-B27. The pathogenic role of HLA-B27 is still not clear although various hypotheses are available. On the basis of evidence from trials the cytokines tumour necrosis factor (TNF)-α and interleukin-17 appear to have a relevant role in pathogenesis. The mechanisms of interaction between inflammation and new bone formation is still not completely understood but clarification will be important for the prevention of long-term structural damage of the bone. The development of new criteria for classification and for screening of patients with axial spondyloarthritis have been crucial for the early indentification and treatment of such patients, with MRI being the most important existing imaging method. Non-steroidal anti-inflammatory drugs and TNF blockers are effective therapies. Blockade of interleukin-17 is a new and relevant treatment option. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
- Author
-
Braun, Jürgen, Baraliakos, Xenofon, Deodhar, Atul, Baeten, Dominique, Sieper, Joachim, Emery, Paul, Readie, Aimee, Martin, Ruvie, Mpofu, Shephard, Richards, Hanno B., and MEASURE 1 study group
- Subjects
THERAPEUTIC use of monoclonal antibodies ,SYMPTOMS ,ANKYLOSING spondylitis ,ANTIRHEUMATIC agents ,CANDIDIASIS ,COMPARATIVE studies ,CROHN'S disease ,RESEARCH methodology ,MEDICAL cooperation ,MONOCLONAL antibodies ,NEUTROPENIA ,PSORIASIS ,RADIOGRAPHY ,RESEARCH ,UVEITIS ,EVALUATION research ,RANDOMIZED controlled trials ,DIAGNOSIS - Abstract
Objective: To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS).Methods: In the phase III MEASURE 1 study, patients were randomised to receive intravenous secukinumab 10 mg/kg (at baseline, week 2 and week 4) followed by subcutaneous secukinumab 150 mg (intravenous 150 mg; n=125) or 75 mg (intravenous 75 mg; n=124) every four weeks, or matched placebo (n=122). Placebo-treated patients were re-randomised to subcutaneous secukinumab 150 or 75 mg from week 16. Clinical efficacy assessments included Assessment of SpondyloArthritis international Society 20 (ASAS20) response rates through week 104. Radiographic changes at week 104 were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS).Results: 97 (77.6%) and 103 (83.1%) patients in the intravenous 150 mg and intravenous 75 mg groups, respectively, completed week 104. In the full analysis set (intent-to-treat), ASAS20 response rates at week 104 were 73.7% and 68.0% in the intravenous 150 mg and intravenous 75 mg groups, respectively. Among patients with evaluable X-rays who were originally randomised to secukinumab (n=168), mean change in mSASSS from baseline to week 104 was 0.30±2.53. Serious adverse events were reported in 12.2% and 13.4% of patients in the 150 mg and 75 mg groups, respectively.Conclusions: Secukinumab improved AS signs and symptoms through 2 years of therapy, with no unexpected safety findings. Data from this study suggest a low mean progression of spinal radiographic changes, which will need to be confirmed in longer-term controlled studies.Trial Registration Number: NCT01358175. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
- Author
-
Wei, James C. ‐ C., Baeten, Dominique, Sieper, Joachim, Deodhar, Atul, Bhosekar, Vaishali, Martin, Ruvie, and Porter, Brian
- Subjects
ANKYLOSING spondylitis ,ANKYLOSING spondylitis treatment ,ANKYLOSIS ,PLACEBOS ,DIAGNOSIS ,PATIENTS - Abstract
Aim To evaluate efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis ( AS) via a pooled subgroup analysis from two phase 3 studies, MEASURE 1 ( NCT01358175) and MEASURE 2 ( NCT01649375). Methods In MEASURE 1, patients were randomized to intravenous secukinumab 10 mg/kg or placebo at baseline, Weeks 2 and 4, followed by subcutaneous (s.c.) secukinumab 150 mg, 75 mg or placebo every 4 weeks (q4w) at Week 8. In MEASURE 2, patients were randomized to s.c. secukinumab 150 mg, 75 mg or placebo at baseline, Weeks 1, 2 and 3, and q4w starting at Week 4. Efficacy outcomes were SpondyloArthritis International Society ( ASAS) 20/40, high-sensitivity C-reactive protein (hs CRP), ASAS5/6, Bath Ankylosing Spondylitis Disease Activity Index, Short Form-36 physical component summary, AS quality of life (QoL), ASAS partial remission, and Ankylosing Spondylitis Disease Activity Score - CRP at Weeks 16 and 52. Due to lack of efficacy, the secukinumab 75 mg dose in MEASURE 2 was excluded from this pooled Asian subgroup analysis. Safety analysis included patients who received ≥ 1 dose of study treatment. Results Of 517 patients enrolled into the MEASURE studies, 69 (13.3%) were Asians: 46 in pooled secukinumab and 23 in placebo. At Week 16, ASAS20/40 responses in Asian patients were 69.6%/43.5% with pooled secukinumab versus 26.1%/17.4% with placebo, which were comparable with rates reported in the overall study population. Secukinumab improved predefined efficacy endpoints at Week 16, with responses sustained through Week 52. Secukinumab was well tolerated in Asian patients, with a safety profile consistent with that reported in the overall study population. Conclusion Secukinumab improved signs and symptoms, physical function, and disease-specific QoL in Asian patients with active AS. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
- Author
-
Sieper, Joachim, Deodhar, Atul, Marzo-Ortega, Helena, Aelion, Jacob A., Blanco, Ricardo, Tseng Jui-Cheng, Andersson, Mats, Porter, Brian, Richards, Hanno B., Jui-Cheng, Tseng, and MEASURE 2 Study Group
- Subjects
THERAPEUTIC use of monoclonal antibodies ,ANKYLOSING spondylitis ,ANTIRHEUMATIC agents ,CLINICAL trials ,COMPARATIVE studies ,INTERLEUKINS ,RESEARCH methodology ,MEDICAL cooperation ,MONOCLONAL antibodies ,REOPERATION ,RESEARCH ,TUMOR necrosis factors ,EVALUATION research ,RANDOMIZED controlled trials ,BLIND experiment ,SEVERITY of illness index ,CHEMICAL inhibitors - Abstract
Background: There is significant unmet need in patients with ankylosing spondylitis (AS) who have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment. Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms of AS in the MEASURE 2 study (NCT01649375).Methods: Subjects with active AS (N=219) received secukinumab (150 or 75 mg) or placebo at baseline, weeks 1, 2, 3 and 4, and every 4 weeks thereafter. Randomisation was stratified by prior anti-TNF use: anti-TNF-naive or inadequate response/intolerance to one anti-TNF (anti-TNF-IR). The primary endpoint was Assessment of SpondyloArthritis International Society criteria (ASAS) 20 at week 16.Results: At week 16, 68.2% of anti-TNF-naive subjects treated with secukinumab 150 mg achieved ASAS20 compared with 31.1% treated with placebo (p<0.001). In the anti-TNF-IR group, 50.0% of subjects treated with secukinumab 150 mg achieved an ASAS20 response compared with 24.1% treated with placebo (p<0.05). Numerically greater improvements were observed with secukinumab than with placebo for most secondary endpoints. Clinical responses were sustained through week 52.Conclusions: Secukinumab 150 mg provided sustained improvements in signs and symptoms of AS in anti-TNF-naive and anti-TNF-IR subjects through 52 weeks of therapy.Trial Registration Number: NCT01649375. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
30. New treatment targets for axial spondyloarthritis.
- Author
-
Sieper, Joachim
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *ANKYLOSING spondylitis , *BIOTHERAPY , *BONE growth , *INTERLEUKINS , *MONOCLONAL antibodies , *NONSTEROIDAL anti-inflammatory agents , *SPONDYLOARTHROPATHIES , *TUMOR necrosis factors , *RITUXIMAB , *TREATMENT effectiveness , *ABATACEPT , *TOCILIZUMAB , *CHEMICAL inhibitors - Abstract
Axial spondyloarthritis (axSpA) patients can be divided into those with structural damage in the SI joint visible on X-rays, termed radiographic axSpA or AS, and those in an earlier phase of the disease, without structural damage in the SI joint, termed non-radiographic axSpA. TNF-blockers have been shown to be highly effective in the treatment of active axSpA. Interestingly, conventional DMARDs and also non-TNF-blocker biologics targeting IL-1, IL-6 and T cells (abatacept) are not effective. Recent interest has focused on the cytokines IL-23 and IL-17 as potential treatment targets in axSpA. An open-label trial with ustekinumab showed a good efficacy in AS patients. Two placebo-controlled phase 3 trials with a mAb blocking IL-17, secukinumab, showed a good reduction in disease activity, similarto that shown for TNF blockers. Probably triggered by inflammation, new bone formation is another hallmark in AS and a potentially important treatment target. However, a previously reported inhibitory effect of NSAID treatment could not be confirmed in a recent NSAID trial. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
- Author
-
Sieper, Joachim, Rudwaleit, Martin, Lenaerts, Jan, Wollenhaupt, Jürgen, Myasoutova, Leysan, Park, Sung-Hwan, Yeong W. Song, Ruji Yao, Huyck, Susan, Govoni, Marinella, Chitkara, Denesh, and Vastesaeger, Nathan
- Subjects
- *
NAPROXEN , *STATISTICS , *COMBINATION drug therapy , *CONFIDENCE intervals , *ANKYLOSING spondylitis , *MULTIVARIATE analysis , *INFLIXIMAB , *FISHER exact test , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *TUMOR necrosis factors , *RESEARCH funding , *DATA analysis , *ODDS ratio , *LOGISTIC regression analysis , *DISEASE remission - Abstract
Objectives. To evaluate partial remission during treatment with infliximab (IFX) + naproxen (NPX) vs NPX alone in patients from the two subgroups of SpA and explore baseline predictors of partial remission. Methods. Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial was a double-blind, randomised controlled trial of IFX in biologic-naïve patients with early, active axial SpA. Patients were randomised (2:1) to receive 28 weeks of treatment with i.v. IFX 5 mg/kg (weeks 0, 2, 6, 12, 18 and 24) + NPX 1000 mg/day or i.v. placebo (PBO) + NPX 1000 mg/day. The current post hoc analysis evaluated outcomes in patients who did or did not meet modified New York radiographic criteria for AS. Results. The analysis included 94 patients who met AS criteria and 56 with non-radiographic axial SpA (nr-axSpA). At week 28, Assessment of SpondyloArthritis international Society (ASAS) partial remission was greater with IFX + NPX than PBO + NPX for both the AS group (70.5 vs 33.3%, respectively) and the nr-axSpA group (50.0 vs 37.5%, respectively). A similar pattern occurred with several efficacy measures. Larger treatment effects occurred in the AS group than the nr-axSpA group, possibly due to baseline differences in disease characteristics. Multivariable analyses identified the type of treatment, age and HLA-B27 status as predictors of ASAS partial remission in the total study population. MRI sacroiliac joint scores were associated with partial remission during IFX +NPX treatment. Conclusion. Patients with AS had greater partial remission with IFX +NSAID than NSAID therapy alone; patients with nr-axSpA had a smaller treatment effect. Baseline disease characteristics and age were associated with partial remission with IFX therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
32. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.
- Author
-
Balazcs, Eva, Sieper, Joachim, Bickham, Kara, Mehta, Anish, Frontera, Nancy, Stryszak, Paul, Popmihajlov, Zoran, and Peloso, Paul M.
- Subjects
- *
BICYCLIC compounds , *NAPHTHALENEACETIC acid , *ANTIARTHRITIC agents , *ANTIPYRETICS , *BEDRIDDEN persons - Abstract
Background: This study evaluated two doses of etoricoxib (60 and 90 mg) vs. naproxen 1000 mg in subjects with ankylosing spondylitis (AS). Methods: This was a 2-part, double-blind, active comparator-controlled non-inferiority study in subjects ≥18 years of age with AS. In Part I, subjects were randomized to naproxen 1000 mg; etoricoxib 60 mg, and 90 mg. In Part II, naproxen and etoricoxib 90 mg subjects continued on the same treatment; subjects on etoricoxib 60 mg either continued on 60 mg or escalated to 90 mg. Part I (6 weeks) assessed the efficacy of A) etoricoxib 60 mg vs. naproxen and B) 90 mg vs. naproxen according to the time-weighted average change from baseline in Spinal Pain Intensity (SPI; 0-100 mm VAS) (primary endpoint). The non-inferiority margin was set at 8 mm for SPI. In Part II (20 weeks) we evaluated the potential benefit of increasing from 60 to 90 mg (predefined minimum clinically important difference = 6 mm in SPI) for inadequate responders (<50 % improvement from baseline in SPI) on etoricoxib 60 mg in Part I. Results: In total, 1015 subjects were randomized to receive etoricoxib 60 mg (N = 702), etoricoxib 90 mg (N = 156), and naproxen 1000 mg (N = 157); 70.9 % were male and the mean age was 45.2 years. There were 919 subjects who completed Part I and all continued to Part II. In Part I, SPI change was non-inferior for both etoricoxib doses vs. naproxen. In both Part I and II, the incidence of adverse events (AEs), drug-related AEs, and serious adverse events (SAEs) were similar between the 3 treatment groups. Conclusion: Both doses of etoricoxib were non-inferior to naproxen. All treatments were well tolerated. Etoricoxib 60 and 90 mg effectively control pain in patients with AS, with 60 mg once daily as the lowest effective dose for most patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis.
- Author
-
Bleil, Janine, Maier, Rene, Hempfing, Axel, Sieper, Joachim, Appel, Heiner, and Syrbe, Uta
- Subjects
BONE remodeling ,ANKYLOSING spondylitis ,BONES ,DYES & dyeing ,FISHER exact test ,GRANULATION tissue ,IMMUNOHISTOCHEMISTRY ,LONGITUDINAL method ,OSTEOARTHRITIS ,PROBABILITY theory ,RESEARCH funding ,ZYGAPOPHYSEAL joint ,OSTEOBLASTS ,DESCRIPTIVE statistics - Abstract
Objective We previously suggested that fibroblast-rich granulation tissue eroding the subchondral bone is instrumental in the joint remodeling that occurs in ankylosing spondylitis (AS). The purpose of this study was to determine if this granulation tissue also carries bone-forming capabilities, which we approached by searching for bone-forming cells (hypertrophic chondrocytes, osteoblasts) in its vicinity. We also assessed adipogenic tissue transformation, which has been suggested to be an intermediate feature in AS bone formation based on imaging studies. Methods The facet joints of AS patients, osteoarthritis (OA) patients, and autopsy subjects (controls) were screened for subchondral granulation tissue. We searched for hypertrophic chondrocytes by assessing RUNX-2, type X collagen, and matrix metalloproteinase 13 (MMP-13) expression, for osteoblasts by analyzing RUNX-2, CD56, and type I collagen expression, as well as for signs of new bone formation. Adipocytes and lipid accumulation were assessed in Safranin O-stained sections. Results In the joints of AS and OA patients, RUNX-2-positive cells were found to be lining the granulation tissue. These cells coexpressed type I collagen but lacked type X collagen and MMP-13 expression, confirming their osteoblastic nature. In 91% of AS joints and in 20% of OA joints ( P < 0.05), we observed foci of new bone formation at contact zones between the granulation tissue and the cartilage. Joints containing bony spots showed greater replacement of the adjacent bone marrow by granulation tissue than did joints without bone formation ( P < 0.05). The granulation tissue often contained adipocytes and lipid accumulations. Replacement of the subchondral bone marrow by fat tissue was also frequently found but was not associated with new bone formation. Conclusion The subchondral granulation tissue carries osteoblasts, which promote new bone formation, leading to intraarticular ankylosis of the facet joints in AS. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. New evidence on the management of spondyloarthritis.
- Author
-
Sieper, Joachim and Poddubnyy, Denis
- Subjects
- *
ANKYLOSING spondylitis treatment , *ANTIRHEUMATIC agents , *C-reactive protein , *INFLAMMATION , *NONSTEROIDAL anti-inflammatory agents , *DIPHOSPHONATES , *THERAPEUTIC use of monoclonal antibodies , *THERAPEUTIC use of proteins , *ANKYLOSING spondylitis , *MAGNETIC resonance imaging , *RADIOGRAPHY , *SPONDYLOARTHROPATHIES , *TUMOR necrosis factors , *DISEASE management , *CHEMICAL inhibitors ,THERAPEUTIC use of glucocorticoids - Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for patients with symptomatic axial spondyloarthritis (SpA), who seem to respond best if treated early in the course of disease. The effect of NSAIDs on radiographic disease progression is less clear. Conventional disease-modifying antirheumatic drugs (DMARDs) are not recommended in the treatment of axial SpA, either alone or in combination with TNF blockers. Patients with nonradiographic axial SpA (nr-axSpA) seem to respond as well to TNF blockers as do patients with radiographic axial SpA (ankylosing spondylitis (AS)). However, patients with nr-axSpA should, in addition to a high severity of symptoms, also have objective signs of inflammation, detectable by MRI or by C-reactive protein testing, to be treated with TNF blockers. Whether early TNF-blocker treatment can retard new bone formation needs clarification. In clinical trials, anti-IL-17 agents and TNF blockers showed similar efficacy in patients with AS. The potential of IL-23 blockade for treatment of axial SpA needs to be further investigated. Treatment options for peripheral SpA have been much less thoroughly investigated than those for axial SpA. However, some data indicate that TNF blockers are effective for treating peripheral arthritis, enthesitis and dactylitis, the typical manifestations of peripheral SpA. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis—3-Year data of the ESTHER trial.
- Author
-
Song, In-Ho, Hermann, Kay-Geert, Haibel, Hildrun, Althoff, Christian E., Poddubnyy, Denis, Listing, Joachim, Weiß, Anja, Freundlich, Bruce, Lange, Ekkehard, Rudwaleit, Martin, and Sieper, Joachim
- Abstract
Objective To assess the relationship between active inflammation and development of chronic lesions in the spine and sacroiliac (SI)-joints on MRI in early axial spondyloarthritis (SpA) during treatment with etanercept. Methods Here, we analyzed the 41 patients of the ESTHER trial, who were treated with etanercept over 3 continuous years and of whom MRIs were available for baseline, year 2, and year 3. MRIs were scored for active inflammation (STIR sequences) and chronic changes (T1 sequence) such as fatty lesions, erosions, and ankylosis in the SI joints and spinal vertebral units (VUs). Results The mean fatty lesion scores increased between baseline and year 2 both in the spine (1.13 at baseline vs. 1.40 at year 2, p = 0.0254) and in the SI joints (4.76 at baseline vs. 5.46 at year 2, p = 0.27), but we found no further increase of the fatty lesion score between years 2 and 3. New fatty lesions at years 2 and 3 developed nearly exclusively in SI joint quadrants and VUs in which active MRI inflammation was present at baseline. Fatty lesions disappeared only in 3 SI joint quadrants and in none of VUs at years 2 and 3. Erosion and ankylosis scores remained unchanged. Conclusion Our data indicate a relationship between the presence of active MRI inflammation and the new development of fatty lesions. Furthermore, there was no increase of fatty lesions during continuous treatment of axial SpA patients with etanercept after successful suppression of active inflammation. Whether this is predictive of stopping radiographic progression needs to be further investigated. Significance and Innovations • This is the first study prospectively following inflammatory lesions, including fatty lesions on MRI of spine and sacroiliac joints of patients with early axial SpA treated over 3 years of continuous treatment with a TNF-inhibitor. • No further increase of fatty lesions between year 2 and year 3 was found in early axial SpA patients treated continuously with etanercept. • Our data indicate a strong relationship between the presence of active MRI inflammation and the new development of fatty lesions. • Whether this is predictive of stopping radiographic progression needs to be further investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
36. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
- Author
-
Baraliakos, Xenofon, Borah, Babul, Braun, Juergen, Baeten, Dominique, Laurent, Didier, Sieper, Joachim, Emery, Paul, McInnes, Iain B., van Laar, Jacob M., Wordsworth, Paul, Wollenhaupt, Juergen, Kellner, Herbert, Colin, Laurence, Vandenhende, Francois, Radford, Kath, and Hueber, Wolfgang
- Subjects
ANKYLOSING spondylitis ,DRUG administration ,INTRAVENOUS therapy ,MAGNETIC resonance imaging ,MONOCLONAL antibodies ,QUESTIONNAIRES ,RESEARCH funding ,TIME ,PILOT projects ,TREATMENT effectiveness ,SEVERITY of illness index - Abstract
Introduction: A 28-week study suggested efficacy of the anti-interleukin-17A monoclonal antibody secukinumab in active ankylosing spondylitis (AS). MRI-assessed inflammation was reduced at weeks 6, 28.Objective: To analyse the longer-term effects of secukinumab on MRI inflammatory and non-inflammatory spinal lesions in relation to its clinical efficacy in subjects with active AS.Methods: Spinal MRI results (baseline, week 94) for 13 subjects with AS initially treated with secukinumab 2×10 mg/kg intravenously (n=10) or placebo (n=3) and receiving a secukinumab maintenance dose of 3 mg/kg IV every 4 weeks up to week 94 were evaluated by the Berlin score; inflammatory/non-inflammatory (fatty) changes were assessed at vertebral edges (VEs). Results were compared with clinical outcomes.Results: Most of the 13 subjects assessed at week 94 had sustained clinical responses: 8 (62%) achieved Assessment of SpondyloArthritis international Society 20% (ASAS20), including 6 (46%) achieving ASAS40 responses, corresponding to 75% and 83% reductions in the Berlin score, respectively. In the 10 subjects treated with secukinumab throughout the study period, 79/91 (87%) inflammatory VEs at baseline resolved by week 94; new fatty lesions occurred in 39/796 (4.9%) of VEs; 87/124 (70%) VEs with fatty lesions at baseline remained unchanged; 30% were no longer visible.Conclusions: In this pilot study, secukinumab treatment up to 2 years yielded sustained clinical improvement accompanied by regression of spinal inflammation. The impact of secukinumab on the development of fatty changes and bone formation in AS will be assessed in larger trials.Trial Registration Number: This study is registered with ClinicalTrials.gov, number NCT00809159. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
37. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
- Author
-
Baeten, Dominique, Sieper, Joachim, Braun, Jurgen, Baraliakos, Xenofon, Dougados, Maxime, Emery, Paul, Deodhar, Atul, Porter, Brian, Martin, Ruvie, Andersson, Mats, Mpofu, Shephard, Richards, Hanno B., Braun, Jürgen, MEASURE 1 Study Group, and MEASURE 2 Study Group
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *ANKYLOSING spondylitis , *CANDIDIASIS , *CROHN'S disease , *INTERLEUKINS , *MONOCLONAL antibodies , *NEUTROPENIA , *BLIND experiment , *CHEMICAL inhibitors - Abstract
Background: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis.Methods: In two double-blind trials, we randomly assigned patients to receive secukinumab or placebo. In MEASURE 1, a total of 371 patients received intravenous secukinumab (10 mg per kilogram of body weight) or matched placebo at weeks 0, 2, and 4, followed by subcutaneous secukinumab (150 mg or 75 mg) or matched placebo every 4 weeks starting at week 8. In MEASURE 2, a total of 219 patients received subcutaneous secukinumab (150 mg or 75 mg) or matched placebo at baseline; at weeks 1, 2, and 3; and every 4 weeks starting at week 4. At week 16, patients in the placebo group were randomly reassigned to subcutaneous secukinumab at a dose of 150 mg or 75 mg. The primary end point was the proportion of patients with at least 20% improvement in Assessment of Spondyloarthritis International Society (ASAS20) response criteria at week 16.Results: In MEASURE 1, the ASAS20 response rates at week 16 were 61%, 60%, and 29% for subcutaneous secukinumab at doses of 150 mg and 75 mg and for placebo, respectively (P<0.001 for both comparisons with placebo); in MEASURE 2, the rates were 61%, 41%, and 28% for subcutaneous secukinumab at doses of 150 mg and 75 mg and for placebo, respectively (P<0.001 for the 150-mg dose and P=0.10 for the 75-mg dose). The significant improvements were sustained through 52 weeks. Infections, including candidiasis, were more common with secukinumab than with placebo during the placebo-controlled period of MEASURE 1. During the entire treatment period, pooled exposure-adjusted incidence rates of grade 3 or 4 neutropenia, candida infections, and Crohn's disease were 0.7, 0.9, and 0.7 cases per 100 patient-years, respectively, in secukinumab-treated patients.Conclusions: Secukinumab at a subcutaneous dose of 150 mg, with either subcutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16. Secukinumab at a subcutaneous dose of 75 mg resulted in significant improvement only with a higher intravenous loading dose. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT01358175 and NCT01649375.). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
38. Editorial: Inflammatory Back Pain and Axial Spondyloarthritis: Lessons for Clinical Practice and Epidemiologic Research.
- Author
-
Dubreuil, Maureen and Sieper, Joachim
- Subjects
- *
ANKYLOSING spondylitis , *ANKYLOSING spondylitis treatment , *BACKACHE , *EPIDEMIOLOGICAL research , *INFLAMMATION , *MEDICAL practice , *NATURAL language processing , *PRIMARY health care , *SERIAL publications , *TUMOR necrosis factors , *PHENOTYPES , *COMORBIDITY , *ELECTRONIC health records , *DISEASE complications , *DIAGNOSIS - Abstract
An editorial is presented for Inflammatory Back Pain(IBP) and Axial Spondyloarthritis for Clinical Practice and Epidemiologic Research. Topics discussed include a study conducted by Wang and colleagues onset IBP in the Rochester Epidemiology Project; highlights lost opportunities in the community care of patients with back pain in U.S; and suggest that standardized assessment of patients with chronic back pain is required.
- Published
- 2018
- Full Text
- View/download PDF
39. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
- Author
-
van der Heijde, Désirée, Breban, Maxime, Halter, Dale, DiVittorio, Gino, Bratt, Johan, Cantini, Fabrizio, Kary, Sonja, Pangan, Aileen L., Kupper, Hartmut, Rathmann, Suchitrita S., Sieper, Joachim, and Mease, Phillip J.
- Subjects
SPINE physiology ,ADALIMUMAB ,ACADEMIC medical centers ,ANKYLOSING spondylitis ,LONGITUDINAL method ,MULTIVARIATE analysis ,PLACEBOS ,QUALITY of life ,QUESTIONNAIRES ,REGRESSION analysis ,RESEARCH funding ,STATISTICS ,WORLD health ,DATA analysis ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,PHYSICAL activity ,THERAPEUTICS - Abstract
Objective. Chronic pain and progressive loss of physical function with AS may adversely affect health-related quality of life (HRQoL). The objective of this study was to assess the 5-year data regarding spinal mobility, physical function and HRQoL in patients with AS who participated in the Adalimumab Trial Evaluating Long-term Efficacy and Safety for AS (ATLAS) study. Methods. Patients received blinded adalimumab 40mg or placebo every other week for 24 weeks, then open-label adalimumab for up to 5 years. Spinal mobility was evaluated using linear BASMI (BASMI
lin ). BASDAI, total back pain, CRP, BASFI, Short Form-36 and AS quality of life (ASQoL) were also assessed. Correlations between BASMIlin and clinical, functional and ASQoL outcomes after 12 weeks and after 5 years of adalimumab exposure were evaluated using Spearman's rank correlation. Associations were further analysed using multivariate regression. Results. Three hundred and eleven patients received 51 dose of adalimumab; 125 of the 208 patients originally randomized to adalimumab received treatment for 5 years. Improvements in BASMIlin were sustained through 5 years, with a mean change of -0.6 from baseline in the population who completed 5 years of treatment with adalimumab. Improvements in disease activity, physical function and ASQoL were also sustained through 5 years. BASMIlin was significantly correlated with all evaluated clinical outcomes (P<0.001). The highest correlation was with BASFI at 12 weeks (r = 0.52) and at 5 years (r = 0.65). Multivariate regression analysis confirmed this association (P<0.001). Conclusion. Treatment with adalimumab for up to 5 years demonstrated sustained benefits in spinal mobility, disease activity, physical function and HRQoL in patients with active AS. Spinal mobility was significantly associated with short- and long-term physical function in these patients. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
40. Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression.
- Author
-
Syrbe, Uta, Callhoff, Johanna, Conrad, Kristina, Poddubnyy, Denis, Haibel, Hildrun, Junker, Susann, Frommer, Klaus W., Müller‐Ladner, Ulf, Neumann, Elena, and Sieper, Joachim
- Subjects
ANKYLOSING spondylitis ,ARTHRITIS ,C-reactive protein ,CONFIDENCE intervals ,FAT cells ,SPINE diseases ,RHEUMATOLOGY ,HLA-B27 antigen ,DATA analysis ,BODY mass index ,RECEIVER operating characteristic curves ,ADIPONECTIN ,DESCRIPTIVE statistics ,ODDS ratio ,SYMPTOMS ,DIAGNOSIS - Abstract
Objective Adipokines have metabolic and inflammatory functions but can also affect bone metabolism. The purpose of this study was to determine the relationship between serum levels of adiponectin, resistin, and visfatin and markers of inflammation, disease activity, and radiographic spinal progression in patients with ankylosing spondylitis (AS). Methods Levels of adiponectin, resistin, and visfatin in the serum of 86 AS patients and 25 healthy controls were measured by enzyme-linked immunosorbent assay at baseline. Radiographic spinal progression was determined by the scoring of radiographs of the spine obtained at baseline and after 2 years. Results Mean (±SD) baseline levels of resistin and visfatin were significantly higher in AS patients than in healthy controls (11.6 ± 10.6 ng/ml versus 6.6 ± 3.2 ng/ml [ P = 0.01] for resistin, and 20.9 ± 48.3 ng/ml versus 3.4 ± 2.6 ng/ml [ P = 0.001] for visfatin). Adipokine serum levels did not correlate with disease activity or functional indices. Only resistin serum levels correlated with markers of inflammation. Baseline levels of visfatin, but not resistin or adiponectin, were significantly higher in patients with worsening of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) by ≥2 units after 2 years (n = 19) as compared to patients without mSASSS worsening (37.7 ± 57.8 ng/ml versus 16.1 ± 44.6 ng/ml; P = 0.029) and in patients with syndesmophyte formation/progression (n = 22) as compared to patients without such progression (37.1 ± 55.3 ng/ml versus 15.3 ± 44.8 ng/ml; P = 0.023). Visfatin levels of >8 ng/ml at baseline were predictive of subsequent radiographic spinal progression (adjusted odds ratio 3.6 for mSASSS progression and 5.4 for syndesmophyte formation/progression). Conclusion Serum levels of resistin and visfatin are elevated in AS patients. Elevated visfatin levels at baseline are predictive of subsequent progression of radiographic damage in AS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
41. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.
- Author
-
Song, In-Ho, Hermann, Kay-Geert, Haibel, Hildrun, Althoff, Christian E., Poddubnyy, Denis, Listing, Joachim, Weiß, Anja, Lange, Ekkehard, Freundlich, Bruce, Rudwaleit, Martin, and Sieper, Joachim
- Subjects
ARTHRITIS diagnosis ,SPINE diseases diagnosis ,SPONDYLOLYSIS ,SPINE ,OSTEITIS ,CONFIDENCE intervals ,MAGNETIC resonance imaging ,RHEUMATOLOGY ,SERIAL publications ,DATA analysis ,SPONDYLOARTHROPATHIES ,PREVENTION ,DIAGNOSIS ,ANATOMY - Abstract
Objective. The aim of this study was to assess the degree of fluctuation of osteitis on MRI during long-term treatment with etanercept (ETN) in patients with early axial SpA (axSpA) with active inflammation (osteitis) on whole-body MRI in the spine and/or the SI joints at baseline.Methods. We analysed MRI data from 328 SI joint quadrants and 943 spine vertebral units (VUs) in terms of osteitis in the pooled data set of 41 patients who were treated with ETN for 3 consecutive years. Scoring was performed by two blinded radiologists at baseline, year 2 and year 3.Results. Through years 2 and 3, osteitis on MRI resolved completely in 56 of 144 (38.9%) SI joint quadrants and in 20 of 40 (50%) VUs affected at baseline, while persistent osteitis was found in 24 of 144 (16.7%) SI joint quadrants and in 8 of 40 (20.0%) spine VUs. The development of new osteitis in sites that were free of osteitis at baseline only occurred in 2 of 131 (1.5%) SI joint quadrants and in 3 of 862 (0.4%) spine VUs in both year 2 and year 3.Conclusion. There was a consistently small amount of osteitis on MRI in patients with early axSpA compared with baseline values, and only a very low rate of new-onset osteitis was found during 3 years of continuous treatment with ETN.Trial registration: www.clinicaltrials.gov, NCT00844142. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
42. Histomorphologic and Histomorphometric Characteristics of Zygapophyseal Joint Remodeling in Ankylosing Spondylitis.
- Author
-
Bleil, Janine, Maier, Rene, Hempfing, Axel, Schlichting, Uwe, Appel, Heiner, Sieper, Joachim, and Syrbe, Uta
- Subjects
ACADEMIC medical centers ,BONE remodeling ,ANKYLOSING spondylitis ,BLOOD testing ,IMMUNOHISTOCHEMISTRY ,RESEARCH funding ,SPINE ,DATA analysis software ,MANN Whitney U Test ,KRUSKAL-Wallis Test - Abstract
Objective. To unravel the mechanisms that control bony ankylosis in ankylosing spondylitis (AS). Methods. Histomorphologic and histomorphometric analyses were performed on zygapophyseal joints obtained from 18 patients with AS, 9 patients with osteoarthritis (OA), and 10 cadaver donors without a rheumatic disease (controls). The proteoglycan content of the cartilage was determined by Safranin O staining and the chondrocyte apoptosis according to caspase 3 expression. Results. AS joints were categorized into 3 groups according to the morphology of the joint surfaces and joint space: group 1 were joints with an open joint space, group 2 were joints with cartilaginous fusion, and group 3 were joints with bony fusion of the joint surfaces. Progressive loss of the joint space from group 1 joints to group 3 joints suggests that this grouping corresponds to sequential stages of joint remodeling. Cartilage thickness and subchondral bone plate thickness declined from group 1 to group 3 (P < 0.01). Increased chondrocyte apoptosis rates were found in groups 1 and 2 (P < 0.05), while in group 3, a reduction in the proteoglycan content was found (P < 0.001). Bone marrow replacement and invasion of the subchondral bone plate by fibrous tissue was found predominantly in AS joints in group 2. Conclusion. Cartilage degeneration, indicated by cartilage thinning, enhanced chondrocyte apoptosis, and proteoglycan loss, and subchondral bone thinning, promoted by invasion of the subchondral bone plate by a fibrous tissue originating from the bone marrow, are hallmarks of joint remodeling in AS. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Evaluation of the spinal pain score in AS—a psychometric analysis.
- Author
-
Song, In-Ho, Haibel, Hildrun, Stelling, Elke S., Sieper, Joachim, and Rudwaleit, Martin
- Subjects
ACADEMIC medical centers ,MULTIVARIATE analysis ,PAIN ,REGRESSION analysis ,RESEARCH evaluation ,SPONDYLOARTHROPATHIES ,STATISTICS ,T-test (Statistics) ,LOGISTIC regression analysis ,DATA analysis ,SEVERITY of illness index ,DESCRIPTIVE statistics ,DISEASE complications - Abstract
Objective. To evaluate the spinal pain score (SpiPS), a semi-objective instrument for measuring disease activity in AS.Methods. The SpiPS is based on the physical examination of the spine and was evaluated according to the outcome measures in rheumatology filter in 659 AS patients from different cohorts including two interventional trials. Aspects of truth, discrimination and feasibility were assessed.Results. The SpiPS significantly distinguished between patients with high and low disease activity. The correlation of the SpiPS with the disease activity index BASDAI was relatively weak in the entire cohort of AS patients (r = 0.36) but moderate to good in AS patients with short disease duration (r = 0.66). Correlations with the functional index BASFI (r = 0.38), patient global (r = 0.18), physician global (r = 0.51) and BASMI (r = 0.36) were weak to moderate in the entire cohort. Logistic regression revealed SpiPS and patient global to be independently associated with disease activity (BASDAI) after adjustments for age, gender, disease duration, CRP and HLA-B27. Sensitivity to change expressed as effect size (ES) was 0.82 and 1.58, respectively, and highly comparable with that of BASDAI in the two interventional trials. Reproducibility of the SpiPS was good (intra-observer variability r = 0.93, inter-observer variability r = 0.79).Conclusion. The SpiPS is a measure of disease activity in AS and is sensitive to change. However, disease domains other than disease activity are also captured by the SpiPS, and our analysis failed to demonstrate any additional value of the SpiPS over existing instruments. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
44. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
- Author
-
Van Der Heijde, Désirée, Braun, Jürgen, Dougados, Maxime, Sieper, Joachim, Pedersen, Ronald, Szumski, Annette, and Koenig, Andrew S.
- Subjects
SULFONAMIDE drugs ,ETANERCEPT ,ANALYSIS of covariance ,ANALYSIS of variance ,C-reactive protein ,CHI-squared test ,CONFIDENCE intervals ,MEDICAL cooperation ,QUALITY of life ,RESEARCH ,SPONDYLOARTHROPATHIES ,STATISTICS ,TUMOR necrosis factors ,DATA analysis ,RANDOMIZED controlled trials ,VISUAL analog scale ,BLIND experiment ,DESCRIPTIVE statistics ,CHEMICAL inhibitors ,THERAPEUTICS - Abstract
Objectives. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new composite clinical tool combining subjective and objective measures. Using data from the randomized double-blind Ankylosing Spondylitis Study Comparing Enbrel with Sulfasalazine Dosed Weekly (ASCEND) trial, we tested ASDAS validity and assessed its capacity to discriminate between treatment effects and change-from-baseline improvements.Methods. These post hoc analyses were conducted in patients who received etanercept (50 mg/week) or SSZ (≤3 g/day) for 16 weeks. The ASDAS was tested for its capacity to discriminate between those who achieved and did not achieve Assessment of Spondyloarthritis International Society (ASAS) partial remission and ASAS20. Week 16 adjusted treatment differences and effect sizes of improvement from baseline of 42 outcomes were calculated.Results. Means for ASDAS were less than half in patients with ASAS partial remission compared with patients without partial remission across the entire study population (1.2 vs 2.6; P < 0.0001). Patients who achieved ASAS20 had greater mean changes from baseline in ASDAS than those who did not (−1.8 vs −0.3; P < 0.0001). ASDAS was consistently shown to have one of the highest discriminatory capacities compared with other measurements (including subjective measurements) regardless of normal vs high CRP, presence or absence of peripheral arthritis and high vs very high ASDAS at baseline. As a dichotomous variable using different thresholds for improvement and disease severity, ASDAS had slightly better discriminatory capacity than all corresponding ASAS measures.Conclusion. ASDAS is a validated and highly discriminatory tool for the detection of significant differences between treatments for AS as well as for detecting a significant improvement from baseline with etanercept and SSZ. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
45. Referral strategies for early diagnosis of axial spondyloarthritis.
- Author
-
Rudwaleit, Martin and Sieper, Joachim
- Subjects
- *
SPONDYLOARTHROPATHIES , *ANKYLOSING spondylitis , *THERAPEUTICS , *DIAGNOSIS , *RHEUMATOLOGISTS , *BACKACHE , *HLA-B27 antigen - Abstract
The spectrum of HLA-B27-associated inflammatory spine diseases is referred to as axial spondyloarthritis (axSpA). AxSpA encompasses established ankylosing spondylitis (AS) but also nonradiographic axSpA, and can be classified according to the Assessment of SpondyloArthritis international Society classification criteria for axSpA. Specific and effective therapy for axSpA includes education, physiotherapy, NSAIDs and biologic agents, as appropriate. Patients with axSpA, however, are often diagnosed late in the course of the disease. As specific therapy is available, the effective identification of those individuals who are likely to have axSpA among patients with chronic back pain in primary care and their subsequent referral to a rheumatologist for establishing a correct diagnosis is worth pursuing. Candidate referral parameters that can easily be applied to patients with chronic back pain and age at onset <45 years (the target population) include inflammatory back pain (IBP) and positivity for HLA-B27. Following diagnostic work-up by a rheumatologist, these referral parameters, either alone or in combination, have led to the diagnosis of as many as 33-45% of patients within this target population with axSpA, 41-62% of whom had undiagnosed AS. Thus, educating primary care physicians on the value of IBP and HLA-B27 testing within this target population, and referral to a rheumatologist if one of these parameters is positive, is a promising approach to reduce the long delay in diagnosing patients with axSpA. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
46. Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn's Disease and Ankylosing Spondylitis.
- Author
-
Ergin, Asgar, Syrbe, Uta, Scheer, Rebecca, Thiel, Andreas, Adam, Thomas, Büssow, Konrad, Duchmann, Rainer, Zeitz, Martin, and Sieper, Joachim
- Subjects
ESCHERICHIA coli diseases ,CROHN'S disease ,ANKYLOSING spondylitis ,BACTERIAL proteins ,T cells ,INFLAMMATORY bowel diseases ,IMMUNOREGULATION - Abstract
Background: To clarify the impact of T cell responses towards enteric antigens for chronic intestinal inflammation, we determined T helper 1 reactivity towards conserved Escherichia coli proteins in patients with Crohn's disease (CD) and healthy individuals and patients with ankylosing spondylitis (AS), who also often show microscopic inflammatory lesions within the gut or even develop overt inflammatory bowel disease. Methods: We determined the frequency of IFNγ+CD40L+ cells/CD4+ T cells after stimulation of whole blood with pools of E. coli proteins. Results: The E. coli-specific Th1 response was significantly reduced in CD patients and to a lower extent also in AS patients. Conclusions: E. coli is a target for polyclonal Th1 responses in healthy individuals. The impairment of these responses in CD and AS patients might be due to recruitment of enterobacteria-specific Th1 cells to the gut or might reflect inadequate priming of adaptive immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
47. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome.
- Author
-
Baraliakos, Xenofon, Listing, Joachim, Fritz, Claudia, Haibel, Hildrun, Alten, Rieke, Burmester, Gerd-Rüdiger, Krause, Andreas, Schewe, Stefan, Schneider, Matthias, Sörensen, Helmut, Schmidt, Reinhold, Sieper, Joachim, and Braun, Juergen
- Subjects
ANKYLOSING spondylitis ,AUTOANTIBODIES ,BLOOD testing ,CONFIDENCE intervals ,EPIDEMIOLOGY ,FISHER exact test ,HEALTH outcome assessment ,PLACEBOS ,SAFETY ,T-test (Statistics) ,TUMOR necrosis factors ,LOGISTIC regression analysis ,DATA analysis ,INFLIXIMAB ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,SEVERITY of illness index ,CHEMICAL inhibitors ,PROGNOSIS - Abstract
Objectives. To report for the first time on the efficacy and safety of anti-TNF therapy after 8 years of follow-up in patients with active AS, and analyse possible short-term predictors for long-term clinical outcomes.Methods. In this open-label extension of a randomized controlled trial, proportions of the initially included 69 patients with active AS were treated with infliximab 5 mg/kg i.v./6 weeks for 8 years. The last report was published after 5 years. All analyses were based on completers.Results. Overall, 33 (48%) patients completed 8 years. Their mean (s.d.) BASDAI [2.6 (1.9)], BASFI [3.3 (2.6)] and BASMI [2.7 (2.4)] remained low at Year 8. At the end of Year 8, most patients were either in partial remission (n = 8, 24%) or had low disease activity (BASDAI < 3; n = 21, 64%). No new serious adverse events occurred within the past 3 years. Adverse events were the most frequent reason for dropout (56%). There were no differences between completers and dropouts at baseline, but the latter had higher BASFI values at dropout. No baseline parameter was associated with good long-term response to infliximab, but lower BASDAI levels after 12 weeks were predictive of a higher probability of partial remission [odds ratio (OR) 2.9, 95% CI 1.3, 6.3, P = 0.007], low disease activity (OR 1.7, 95% CI 1.2, 2.3, P = 0.005) or remaining on treatment (OR 0.79, 95% CI 0.61, 1.01, P = 0.06) after 8 years.Conclusion. Almost half of the initially treated patients remained on anti-TNF therapy for 8 years, and almost 90% were in partial remission or had low disease activity. Short-term response (low BASDAI at 3 months) is predictive of outcome after 8 years. Infliximab therapy was safe over 8 years. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
48. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.
- Author
-
Neilson, Aileen R., Sieper, Joachim, and Deeg, Maria
- Subjects
- *
ANKYLOSING spondylitis treatment , *ETANERCEPT , *COST effectiveness , *DATABASES , *QUALITY of life - Abstract
Objectives. To estimate the cost-effectiveness of etanercept (ETN) plus usual care (including NSAIDs) compared with usual care alone (including NSAIDs) in patients with severe AS in Germany.Methods. A mathematical model previously applied to the UK was adapted using resource use and cost data (for 2007) from the national database of the German Collaborative Arthritis Centres. Social health insurance (SHI) and societal perspectives were analysed. Assumptions on initial response and changes in health-related quality of life were based on Phase III randomized controlled trials. Initial treatment response according to British Society for Rheumatology guidelines were assumed as a conservative estimate in the German context. Long-term disease progression was based on the available literature. Incremental cost–effectiveness ratios (ICERs) were expressed as euros/quality-adjusted life year (QALY), for a cohort of 1000 patients over 25 years. Sensitivity analyses explored uncertainty in results.Results. In the base case, ETN plus usual care (including NSAIDs) yielded 1475 more QALYs at an additional cost of €80 827 668 (SHI) or €32 657 590 (societal) leading to an ICER of €54 815/QALY and €22 147/QALY, respectively. Over a shorter time horizon of 10 years, the ICERs were €59 006 and €29 815 for SHI and societal viewpoints, respectively. Assumptions having the largest impact on results included withdrawal rates from ETN, quality of life, disease costs and initial response.Conclusions. Cost-effectiveness for ETN in patients with severe AS in Germany differs according to the cost perspective. Study estimates were higher than in the UK but comparable with reported cost-effectiveness of anti-TNF treatments in patients with RA in Germany. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
49. Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis.
- Author
-
Inman, Robert D., Davis Jr., John C., van der Heijde, Désirée, Diekman, Laura, Sieper, Joachim, Sung Il Kim, Mack, Michael, Han, John, Visvanathan, Sudha, Zhenhua Xu, Benjamin Hsu, Beutler, Anna, and Braun, Jürgen
- Subjects
ANKYLOSING spondylitis ,TREATMENT of spine diseases ,IMMUNOSUPPRESSIVE agents ,DRUG side effects ,DRUG utilization - Abstract
The article focuses on a study which evaluates the efficacy and safety of golimumab among patients who have ankylosing spondylitis (AS). The methods used and the significant findings from the study are discussed. Assessments reveal that golimumab is effective and well-tolerated by the patients with AS during the period of the study.
- Published
- 2008
- Full Text
- View/download PDF
50. A case of axial undifferentiated spondyloarhritis diagnosis and management.
- Author
-
Rudwaleit, Martin and Sieper, Joachim
- Subjects
- *
LUMBAR vertebrae , *BACKACHE , *MAGNETIC resonance imaging , *ERYTHROCYTES , *C-reactive protein , *LEUCOCYTES - Abstract
Background A 32-year-old white man presented with features of inflammatory back pain, including awakening at night and morning stiffness. He had acute back pain 4 years earlier as a result of a herniated lumbar disc. Investigations The orthopedic consultation included tests for neurologic deficits; a Lasegue test; a finger-to-floor distance test; X-rays of the lumbar spine; and MRI of the lumbar spine. The rheumatologic consultation included recordal of clinical history and family history; physical examination, including a Schober's test, lateral spine flexion, chest expansion, cervical rotation, and tragus-to-wall distance; blood tests, including genotyping for human leukocyte antigen B27 positivity, and measurements of C-reactive protein level and erythrocyte sedimentation rate; MRI of the sacroiliac joints with use of short tau inversion recovery sequences; and measurement of the Bath Ankylosing Spondylitis Disease Activity Index and the Bath Ankylosing Spondylitis Functional Index. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.